MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults.

Pencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, Bhasin S

The journals of gerontology. Series A, Biological sciences and medical sciences1 Jan 2023Cited by 43 (Europe PMC)

PMID35182418DOI10.1093/gerona/glac049PepBankPUB-35182418

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialSafety outcome
In overweight or obese older adults, adverse event frequency was similar across MIB-626 and placebo groups.
In plain wordsIn overweight or obese older adults, adverse events were similarly frequent with MIB-626 and placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeAdverse event frequency
Study
n = 32
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
1 000 mg once daily or twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
MIB-626 was well tolerated and frequency of adverse events was similar across groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55-80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days.
Report a problemFND-3518241801
02HumanRandomized controlled trialPharmacokinetics
In overweight or obese older adults, MIB-626 treatment was associated with substantial dose-related blood NAD increases.
In plain wordsIn overweight or obese older adults, MIB-626 increased blood NAD levels in relation to dose.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseBlood NAD levels
Study
n = 32
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 000 mg once daily or twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
MIB-626 treatment was associated with substantial dose-related increases in blood NAD levels.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55-80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days.
Report a problemFND-3518241804
03HumanRandomized controlled trialPharmacokinetics
In overweight or obese older adults, once-daily MIB-626 increased blood NMN AUClast above baseline and exceeded placebo on Day 14.
In plain wordsIn overweight or obese older adults, once-daily MIB-626 increased blood NMN exposure more than placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseBlood NMN mean AUClast, once daily
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 000 mg once daily · oral · 14 daysAs given in this study (human).
Measurements
Mean AUClast increase above baseline
1.7 fold
1 000 mg once daily, Day 14
Source sentences
Summary
Blood NMN concentrations on Day 14 in MIB-626-treated groups were significantly higher compared to placebo (1.7-times and 3.7-times increase above baseline in 1 000 mg once-daily and twice-daily groups in mean AUClast, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55-80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days.
Report a problemFND-3518241802
04HumanRandomized controlled trialPharmacokinetics
In overweight or obese older adults, twice-daily MIB-626 increased blood NMN AUClast above baseline and exceeded placebo on Day 14.
In plain wordsIn overweight or obese older adults, twice-daily MIB-626 increased blood NMN exposure more than placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseBlood NMN mean AUClast, twice daily
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 000 mg twice daily · oral · 14 daysAs given in this study (human).
Measurements
Mean AUClast increase above baseline
3.7 fold
1 000 mg twice daily, Day 14
Source sentences
Summary
Blood NMN concentrations on Day 14 in MIB-626-treated groups were significantly higher compared to placebo (1.7-times and 3.7-times increase above baseline in 1 000 mg once-daily and twice-daily groups in mean AUClast, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55-80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days.
Report a problemFND-3518241803
05HumanRandomized controlled trialPharmacokinetics
In NMN-treated older adults, blood NAD metabolite levels were higher on Days 8 and 14 than at baseline.
In plain wordsIn older adults given NMN, blood NAD metabolite levels exceeded baseline on Days 8 and 14.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseBlood NAD metabolites
Study
n: not reported in source
Comparator
Baseline
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 000 mg once daily or twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Blood levels of NAD metabolites were higher in NMN-treated participants on Days 8 and 14 than at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55-80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days.
Report a problemFND-3518241805
06HumanRandomized controlled trialOther
In older trial participants, changes in NMN levels were not related to sex, body mass index, or age.
In plain wordsIn older adults, changes in NMN levels were not linked to sex, body mass index, or age.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeNMN level changes in relation to sex, BMI and age
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 000 mg once daily or twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Changes in NMN or NAD levels were not related to sex, body mass index, or age.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55-80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days.
Report a problemFND-3518241806
07HumanRandomized controlled trialOther
In older trial participants, changes in NAD levels were not related to sex, body mass index, or age.
In plain wordsIn older adults, changes in NAD levels were not linked to sex, body mass index, or age.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeNAD level changes in relation to sex, BMI and age
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 000 mg once daily or twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Changes in NMN or NAD levels were not related to sex, body mass index, or age.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55-80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days.
Report a problemFND-3518241809
08HumanRandomized controlled trialPharmacokinetics
In older trial participants, very little unmodified NMN was excreted in urine.
In plain wordsIn older adults, very little unchanged NMN entered the urine.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reportedUrinary unmodified NMN excretion
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 000 mg once daily or twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Very little unmodified NMN was excreted in the urine.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55-80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days.
Report a problemFND-3518241812

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 1NCT06882096

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

Metro International Biotech, LLCn = 3228 Apr 2025 to est. Jun 2027

Healthy Adults

Trial page ClinicalTrials.govUpdated 6 May 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.